T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.47B |
| 2 |
NXP Semiconductors
NXPI
|
+$1.73B |
| 3 |
Tesla
TSLA
|
+$1.7B |
| 4 |
Northrop Grumman
NOC
|
+$1.67B |
| 5 |
Dollar Tree
DLTR
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.29B |
| 2 |
Meta Platforms (Facebook)
META
|
+$1.85B |
| 3 |
Texas Instruments
TXN
|
+$1.82B |
| 4 |
Microsoft
MSFT
|
+$1.27B |
| 5 |
Booking.com
BKNG
|
+$1.18B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.76% |
| 2 | Technology | 16.79% |
| 3 | Consumer Discretionary | 15.26% |
| 4 | Financials | 14.49% |
| 5 | Industrials | 9.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Viavi Solutions
VIAV
$10.6B
| $14.6M | ﹤0.01% |
1,289,907
+386,322
| +43% | +$4.17M |
|
1302
Rigel Pharmaceuticals
RIGL
$762M
| $14.6M | ﹤0.01% |
454,712
+100,627
| +28% | +$3.02M |
|
1303
Larimar Therapeutics
LRMR
$444M
| $14.5M | ﹤0.01% |
+103,707
| New | +$12.6M |
|
|
FPRX
1304
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $14.5M | ﹤0.01% |
1,041,254
+3,313
| +0.3% | +$49.3K |
|
1305
Western Union
WU
$2.34B
| $14.3M | ﹤0.01% |
748,842
-5,211
| -0.7% | -$101K |
|
|
AYX
1306
DELISTED
Alteryx Inc
AYX
| $14.2M | ﹤0.01% |
+248,455
| New | +$12.7M |
|
|
DISH
1307
DELISTED
DISH Network Corp.
DISH
| $14.1M | ﹤0.01% |
394,150
-6,852
| -2% | -$235K |
|
|
LABL
1308
DELISTED
Multi-Color Corp
LABL
| $14.1M | ﹤0.01% |
225,869
+2,483
| +1% | +$159K |
|
1309
RPC Inc
RES
$1.39B
| $14M | ﹤0.01% |
905,880
+5,452
| +0.6% | +$80.1K |
|
1310
Whirlpool
WHR
$2.79B
| $13.9M | ﹤0.01% |
117,390
-2,126
| -2% | -$282K |
|
1311
CorVel
CRVL
$3.25B
| $13.9M | ﹤0.01% |
693,162
-21,219
| -3% | -$409K |
|
|
FINV
1312
FinVolution Group
FINV
$1.07B
| $13.9M | ﹤0.01% |
2,582,335
+509,298
| +25% | +$2.65M |
|
|
XYZ
1313
Block Inc
XYZ
$49.9B
| $13.8M | ﹤0.01% |
139,562
+26,002
| +23% | +$2.01M |
|
1314
NETSCOUT
NTCT
$2.89B
| $13.8M | ﹤0.01% |
544,619
-1,870
| -0.3% | -$50.5K |
|
|
GRMN
1315
Garmin
GRMN
$60.2B
| $13.6M | ﹤0.01% |
193,894
+20,915
| +12% | +$1.37M |
|
1316
Fluor
FLR
$7B
| $13.5M | ﹤0.01% |
232,524
+5,220
| +2% | +$284K |
|
|
ESPR
1317
DELISTED
Esperion Therapeutics
ESPR
| $13.4M | ﹤0.01% |
303,036
+133
| +0% | +$6.11K |
|
1318
Hilltop Holdings
HTH
$2.28B
| $13.4M | ﹤0.01% |
664,123
-160,244
| -19% | -$3.39M |
|
1319
Royal Gold
RGLD
$19.1B
| $13.3M | ﹤0.01% |
173,231
-30,337
| -15% | -$2.5M |
|
1320
Affiliated Managers Group
AMG
$9.7B
| $13.3M | ﹤0.01% |
97,228
-1,972
| -2% | -$291K |
|
1321
Fate Therapeutics
FATE
$294M
| $13.2M | ﹤0.01% |
813,195
+24,099
| +3% | +$285K |
|
|
TCO
1322
DELISTED
Taubman Centers Inc.
TCO
| $13.2M | ﹤0.01% |
220,765
-152,927
| -41% | -$9.43M |
|
1323
Harley-Davidson
HOG
$2.9B
| $13.2M | ﹤0.01% |
290,702
| – | – |
|
|
NTUS
1324
DELISTED
Natus Medical Inc
NTUS
| $13.1M | ﹤0.01% |
367,234
+58,885
| +19% | +$2.08M |
|
|
TRCO
1325
DELISTED
TRIBUNE MEDIA COMPANY CLASS A
TRCO
| $13.1M | ﹤0.01% |
340,430
+323,107
| +1,865% | +$11.6M |
|
Similar funds
T. Rowe Price Associates's Q3 2018 Portfolio in Review
As of Q3 2018, T. Rowe Price Associates held 2,658 positions worth $685B, up 4.7% from $654B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
T. Rowe Price Associates's Q3 2018 filing shows 77 new, 1,268 increased, 1,098 reduced and 77 closed positions. Its largest new stake was Fortive Corporation 5.00% Mandatory Convertible Preferred Stock, Series A: 194,161 shares worth $208M. The largest sale was Broadcom, an estimated $3.29B.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2018 buy was Fortive Corporation 5.00% Mandatory Convertible Preferred Stock, Series A: 194,161 shares worth $208M.
- T. Rowe Price Associates added most to NVIDIA in Q3 2018, an estimated $2.47B increase.
- T. Rowe Price Associates's biggest Q3 2018 reduction was Broadcom, cutting an estimated $3.29B.
- T. Rowe Price Associates fully exited DCT Industrial Trust Inc. in Q3 2018, selling an estimated $345M.
- T. Rowe Price Associates's ten largest holdings make up 20% of its $685B portfolio in Q3 2018.
- T. Rowe Price Associates opened 77 new positions and closed 77 in Q3 2018.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $685B.
Based on T. Rowe Price Associates's 13F filing for Q3 2018, filed 14 Nov 2018.